KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Rhea-AI Summary

KalVista Pharmaceuticals presented real-world data revealing treatment delays, suboptimal outcomes, and anxiety linked to injectable treatments for Hereditary Angioedema (HAE) patients at AAAAI 2024.

Insights

Medical Research Analyst

The real-world data presented by KalVista Pharmaceuticals regarding patient experiences with injectable on-demand treatments for Hereditary Angioedema (HAE) can have significant implications for the development of new therapeutic strategies. The findings suggest a need for improved treatment protocols that address patient anxiety and barriers to timely administration. This has potential implications for drug developers and the healthcare sector, as it highlights the importance of patient-centric treatment options that could lead to better adherence and clinical outcomes.

Understanding patient behavior and the psychological impact of disease management is crucial for pharmaceutical companies. The data indicating that a considerable proportion of patients delay treatment due to anxiety or the desire to reserve medication for more severe attacks suggests that there may be a market for alternative therapies that are perceived as more accessible or less anxiety-inducing. This could influence the stock performance of companies like KalVista, which are in the process of developing such alternatives, as investors may anticipate increased demand for patient-friendly treatment options.

Healthcare Economist

The economic implications of the findings presented by KalVista Pharmaceuticals extend beyond drug development costs and affect overall healthcare expenditure. Delayed treatment of HAE attacks due to patient barriers such as uncertainty and anxiety can result in more severe health outcomes and, consequently, higher medical costs. By identifying these barriers, there is an opportunity for healthcare systems to invest in patient education and support mechanisms that could reduce the long-term financial burden associated with HAE management.

From an economic perspective, the development of oral, small molecule protease inhibitors, as pursued by KalVista, could lead to a reduction in the cost of treatment and the overall economic burden of HAE. This is because oral medications are typically easier to administer and may be associated with lower levels of anxiety compared to injectables. If such treatments prove to be effective and are adopted widely, this could lead to a shift in healthcare spending patterns, potentially benefiting patients, insurers and the healthcare system at large.

Pharmaceutical Market Analyst

The market for HAE treatments is evolving, with patient experience becoming an increasingly important factor in treatment adoption and brand loyalty. The data presented by KalVista Pharmaceuticals at the AAAAI Annual Meeting could influence the competitive landscape of HAE treatments. If oral, small molecule protease inhibitors demonstrate efficacy and address the concerns highlighted in these patient surveys, they could capture significant market share from injectable treatments.

Investors and stakeholders in the pharmaceutical industry should monitor the progress of KalVista's development pipeline closely, as successful commercialization of their oral treatments could disrupt the market. Additionally, the company's focus on patient-reported outcomes may resonate with regulatory agencies and payers, potentially facilitating drug approval processes and favorable reimbursement policies. This could have a positive impact on KalVista's stock valuation and the broader market for HAE therapies.

– Patient perspectives revealed frequent treatment delays, suboptimal clinical outcomes and substantial anxiety associated with injectable on-demand treatments, including those who received long-term prophylaxis -

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting that took place in Washington, DC.

The following presentations occurred at AAAAI 2024:

• Characteristics of Hereditary Angioedema Attacks Among Long-Term Prophylaxis Users: Bob Geng, Allergy and Immunology, University of California, San Diego, California, United States (Poster Presentation)
  • Among HAE patients who had treated a recent attack, the location and duration of the most recent attacks were similar between long-term prophylaxis (LTP) and on-demand only users
  • Earlier on-demand treatment was associated with a shorter attack duration, regardless of LTP use
• Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers: Sandra Christiansen, University of California San Diego, La Jolla, CA, United States (Poster Presentation)
  • Despite their perception of treating attacks “early”, many patients did not meet guideline recommendations for prompt on-demand treatment after recognition of an HAE attack
  • The most common barriers to earlier treatment were uncertainty if attack was real, thinking the attack would be mild, and wanting to save treatment for a severe attack
• Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks: James Wedner, Washington University School of Medicine, St Louis, MO, United States (Poster Presentation)
  • Both adults and adolescents with HAE reported moderate to extreme anxiety when anticipating use of parenteral on-demand treatment, irrespective of use of on-demand only or on-demand plus LTP
  • The results of this study highlighted the association between delayed treatment and treatment-related anxiety, with a higher proportion of patients who delayed treatment experiencing moderate to extreme anxiety
• Anxiety Associated with Refilling On-demand Therapy for HAE Attacks Contributes to Treatment Delay and Non-Treatment: Autumn Burnette, Division of Allergy and Immunology, Howard University Hospital, Washington, DC, United States (Poster Presentation)
  • Anxiety associated with not being able to refill on-demand treatment quickly impacted treatment decisions, which contributed to treatment delay or resulted in non-treatment of HAE attacks
  • One-third of patients using icatibant did not treat or delayed treatment due to anxiety about refills
• Characterizing the Negative Impact of Delayed On-Demand Treatment of HAE Attacks: Princess Ogbogu, Division of Pediatric Allergy, Immunology, and Rheumatology, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States (Poster Presentation)
  • People living with HAE understood the importance of treating HAE attacks early and recognized that earlier treatment translates to quicker recovery and resolution
  • Delayed on-demand treatment (> 1 hour) lengthened the time to “feeling in control” of an attack and the time to feeling fully recovered
• The Impact of On-demand Treatment on Quality of Life of People with HAE: Paula Busse, Department of Medicine, Division of Clinical Immunology, Mount Sinai, New York, United States (Poster Presentation)
  • People with HAE needed to make adjustments to their daily lives including avoiding situations where their injectable on-demand treatment may be discovered by others
  • Embarrassment associated with carrying on-demand treatment was among the reasons HAE patients delayed administration of on-demand treatment
• Characterizing the Perspective of Patients With HAE on Prophylactic Treatment: Stephen Betschel, Division of Allergy and Immunology, Department of Medicine, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada (Poster Presentation)
  • Only 35% of LTP patients always carried on-demand treatment when away from home, while 43% of prophylaxis patients cited avoiding potential triggers as a reason for not carrying on-demand treatment at all times
  • Nearly half of patients on LTP patients experienced moderate to extreme levels of anxiety when anticipating on-demand treatment administration
• Treatment Patterns of Patients Requiring Redosing of an On-demand Treatment After the Return of an HAE Attack: Constance Katelaris, Department of Medicine, Campbelltown Hospital and Western Sydney University, Sydney, NSW, Australia (Poster Presentation)
  • Almost one third of people with HAE experienced the return of an HAE attack requiring ≥1 additional dose of on-demand treatment
  • HAE attacks treated within 1 hour returned less frequently compared with attacks treated after ≥1 hour

“The results of these surveys clearly conveyed the challenges faced by patients trying to manage their HAE attacks with injectable on-demand treatments. The resulting non-compliance with treatment guidelines may lead to poor clinical outcomes, even among patients receiving LTP,” said Andrew Crockett, Chief Executive Officer of KalVista. “We believe the efficacy and safety data from our phase 3 trial for sebetralstat show a potential path forward to address these persisting unmet needs.”

Links to all posters and presentations can be found on the KalVista website under “Publications”.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista disclosed positive phase 3 data for the KONFIDENT trial for its oral, on-demand therapy sebetralstat in February 2024. The Company anticipates submitting a new drug application to the U.S. FDA for sebetralstat in the first half of 2024 and expects to file for approval in Europe and Japan later in 2024. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.

For more information about KalVista, please visit www.kalvista.com.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including the KONFIDENT-S trial, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2023, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240227931159/en/

KalVista Pharmaceuticals, Inc.

Jarrod Aldom

Vice President, Corporate Communications

(201) 705-0254

jarrod.aldom@kalvista.com

Ryan Baker

Head, Investor Relations

(617) 771-5001

ryan.baker@kalvista.com

Source: KalVista Pharmaceuticals, Inc.

FAQ

What did KalVista Pharmaceuticals present at AAAAI 2024?

KalVista Pharmaceuticals presented real-world data on HAE patient experiences with injectable treatments at AAAAI 2024.

What were the common barriers to earlier treatment according to the patient perceptions study?

Common barriers to earlier treatment included uncertainty if the attack was real, expecting a mild attack, and saving treatment for severe attacks.

What did the study on anxiety associated with refilling on-demand therapy reveal?

The study found that anxiety related to refilling on-demand therapy led to treatment delays or non-treatment of HAE attacks for some patients, with one-third of icatibant users delaying or not treating due to anxiety.